Stem cell rx wins another horse race

This report in from Editorial Administrator and journalist Margaret Guthrie: Earlier this year, we linkurl:reported on a company;http://www.the-scientist.com/news/display/54215/ called Vet-Stem which has devised a treatment for horses using the animal's own stem cells to heal tendon and ligament injuries. In some cases it's been an unqualified success. One of those successes was part of our story - a big gray gelding named Greg's Gold. When we posted the story online, Greg's

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
This report in from Editorial Administrator and journalist Margaret Guthrie: Earlier this year, we linkurl:reported on a company;http://www.the-scientist.com/news/display/54215/ called Vet-Stem which has devised a treatment for horses using the animal's own stem cells to heal tendon and ligament injuries. In some cases it's been an unqualified success. One of those successes was part of our story - a big gray gelding named Greg's Gold. When we posted the story online, Greg's Gold had just won a race on opening day at Santa Anita racetrack, pushing his earnings close to the million dollar mark. The past weekend Greg's Gold ran again, for the ninth time since his treatment. He won easily, beating two other Grade I winners handily (Grade I winners are the top in racehorse land) and pushing his earnings to $1, 067,923. This achievement appears to answer one of the questions skeptics have about the treatment - namely, how long will the previously injured leg hold up? Trainer David Hofmans says, "Yes, the old boy showed up again, he came out of the race great, cleaned out his feed tub, looked around for more." Plans are to run twice more to tune up for the Breeders Cup Sprint and a championship, all on that Vet-Stem repaired leg.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies